HD Bioscience

HD Bioscience is a premier biology-focused contract research organization (CRO) providing comprehensive drug discovery services to global pharmaceutical and biotechnology companies. Founded in 2002 and headquartered in Shanghai, the company offers a wide range of capabilities including plate-based pharmacology, hit identification, lead optimization, and in vivo pharmacology. In early 2017, HD Bioscience was acquired by WuXi AppTec, a move that significantly bolstered WuXi's biology and discovery services. The company operates state-of-the-art facilities in Shanghai, Beijing, and San Diego, supporting research across multiple therapeutic areas such as oncology, inflammation, and metabolic diseases. HD Bioscience is well-regarded for its high-throughput screening platforms and its ability to deliver high-quality data for complex drug discovery programs.